BRIEF — NICE backs AML drug in combo with chemotherapy

Mylotarg (gemtuzumab ozogamicin) has been recommended for National Health Service funding in England and Wales for eligible patients with acute myeloid leukaemia (AML) in combination with chemotherapy.

The Pfizer treatment was recommended for untreated CD33-positive AML by cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) in a final appraisal determination published on Friday.

Craig Eagle, head of oncology, Pfizer UK, said: “We welcome NICE’s final decision to recommend gemtuzumab ozogamicin for eligible patients living with AML.

"Pfizer has worked tirelessly with the AML community to ensure patients in the UK have access to appropriate treatment options and this important, potentially life-changing medicine offers renewed hope for some people living with AML in England and Wales.”